A caller survey by investigators astatine the University of Pittsburgh School of Medicine recovered fewer mild adverse events from monoclonal antibody attraction among large radical with COVID-19, but nary quality successful COVID-19 outcomes.
Monoclonal antibody (mAb) attraction for COVID-19 seems harmless during pregnancy, according to a caller survey that recovered that adverse events aft mAb attraction were mild and rare, but effectiveness was disappointing.
The retrospective, propensity score-matched, cohort study, published successful Annals of Internal Medicine, included 944 large participants affirmative for SARS-CoV-2 corruption enrolled astatine the University of Pittsburgh Medical Center Health System from April 30, 2021, to January 21, 2022.
Investigators evaluated monoclonal antibody attraction with bamlanivimab and etesevimab, casirivimab and imdevimab oregon sotrovimab compared with nary mAb treatment.
“Importantly, mAb attraction seems harmless successful gestation with respect to drug-related adverse events and obstetric-associated outcomes (that is, gestational property astatine delivery, birthweight, stillbirth, NICU admission, hypertension, terrible maternal morbidity, and maternal ICU visit),” the survey authors, led by Erin K. McCreary, PharmD, of the University of Pittsburgh School of Medicine, wrote.
Median property was 30 and 79.5% of participants were white. Median gestational property astatine COVID-19 diagnosis oregon attraction was 179 days, 69% received sotrovimab, and 62% were afloat vaccinated.
Mild drug-related adverse events were reported successful 8 (1.4%) patients treated with mAb, and nary terrible reactions related to mAb infusions were reported. Average gestational property astatine transportation was the aforesaid (273 days) among those who received mAb attraction and those who were untreated. Average birthweight was 3290 grams successful the attraction radical and 3240 among those untreated. There were nary deaths successful the attraction radical and 1 among those untreated.
“In large persons with mild to mean COVID-19, adverse events aft mAb attraction were mild and rare,” the survey authors wrote. “There was nary quality successful obstetric-associated information outcomes betwixt mAb attraction and nary attraction among persons who delievered.”
The survey recovered nary important differences successful COVID-19 outcomes betwixt those treated with mAb and those untreated based connected a composite of hospitalizations, emergecy section visits oregon mortality astatine Day 28.
“In the full population, the hazard ratio for mAb attraction of the composite 28-day COVID-19–associated result was 0.71 (95% CI, 0.37 to 1.4). The propensity score-matched hazard ratio was 0.61 (95% CI, 0.34 to 1.1),” the authors noted.
The survey authors noted that the frequence of hospitalizations and deaths were little than those of the wide population, perchance reflecting the younger age, less comorbidities and precocious complaint of vaccination of the survey group.
“The neutral uncovering from effectiveness models whitethorn beryllium owed to the illustration size of the cohort oregon the lack of a existent attraction effect,” the authors wrote.
The survey couldn’t measure risk-adjusted outcomes for large radical with higher hazard for COVID-19 complications specified arsenic comorbidities oregon unvaccinated status.
More patients successful the attraction radical (14, oregon 2.5%) were hospitalized for non-COVID-19-related issues than successful the untreated radical (2, of 0.5%), but determination was nary quality successful the propensity-matched cohort.
Limitations of the survey included the anticipation of underrepresentation of drug-related adverse events, which were diligent and parovider reported.
A smaller study conducted astatine Yale University School of Medicine besides recovered that sotrovimab was harmless and well-tolerated among large radical and neonates.
English (US)